New ABPA Study Medication

Trial Objective

New ABPA Study MedicationThis study is looking at the effectiveness of different doses of investigational medication itraconazole for adults with asthma and allergic bronchopulmonary aspergillosis (ABPA). Itraconazole is an antifungal medication in powder form that is inhaled directly into the lungs. We are studying this medication to see if it is more effective than oral medication.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Non-smoking adults diagnosed with asthma and ABPA

Age: 18-75    Gender: Any Gender


Estimated Time Commitment

Up to 9 weeks for study treatment, with 8 clinic visits - 3 of which are full day visits



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Allen Stevens

Allen Stevens
303.398.1443

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Pulmatrix

Principal Investigators

Co-Investigators


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More


*
*
*
*